GOSS News and Press, Gossamer Bio Inc. From 05/10/23

2023-05-10 15:14:24 ET Gossamer Bio ( NASDAQ: GOSS ) is undergoing a strategic restructuring that includes laying off more than 25% of its employees and focusing exclusively on seralutinib for pulmonary arterial hypertension. The company said it is on schedule to begin a ...

2023-05-09 17:33:27 ET Gossamer Bio press release ( NASDAQ: GOSS ): Q1 GAAP EPS of -$0.52 beats by $0.02 . $202 million in cash, cash equivalents & marketable securities, as of March 31, 2023 - For further details see: Gossamer Bio GAAP EPS of...

- Feedback on Planned Registrational Program for Seralutinib Received from FDA and EMA following Successful Phase 2 TORREY Study - - Registrational Phase 3 Clinical Trial in PAH Patients Expected to Initiate in 3Q23 - - Initial TORREY Study Open-Label Extension Data Expected Mid 2...

2023-04-03 17:16:58 ET Gossamer Bio ( NASDAQ: GOSS ) is ending development of phase 1 CNS lymphoma candidate GB5121 after the US FDA placed a partial clinical hold on all trials. The company said the hold is due to serious adverse events that have been observed in the ...

2023-04-02 04:12:42 ET Summary Merck's Sotatercept showed significant improvements in PAH patients in Phase 3 STELLAR trial with a primary endpoint of improvements in pulmonary vascular resistance, 6-minute walk distance, and NT-proBNP levels. Gossamer Bio's seralutinib showed cle...

2023-03-27 09:48:13 ET As Wall Street approaches the end of the first quarter, the major U.S. equity averages are trading higher for 2023 so far, despite the turmoil caused by the bank crisis. Still, many traders have made large bets against a handful of well-known names, including Silv...

2023-03-23 09:00:16 ET Advent Technologies Holdings ( ADN ) +34% enter into joint development pact. ZyVersa Therapeutics ( ZVSA ) +26% . BioSig Technologies ( BSGM ) +17% . Aziyo Biologics ( AZYO ) +14% Q4 Earnings call release Generatio...

2023-03-17 07:34:07 ET Gossamer Bio press release ( NASDAQ: GOSS ): Q4 GAAP EPS of -$0.59 beats by $0.03 . Cash, cash equivalents and marketable securities as of December 31, 2022, were $255.7 million. "As a result, we expect our current cash, cash equivalents and ...

- FDA Feedback on Seralutinib Phase 3 Clinical Trial Received; Expected to Commence in the Second Half of 2023 - - Topline Data from TORREY Study Open-Label Extension Expected in Mid-2023 - - Enrollment in GB5121 Phase 1b/2 Clinical Trial in PCNSL Paused - - Cash, cash equ...

2023-03-07 12:08:06 ET Merck’s ( MRK ) newly published full Phase 3 data for sotatercept in pulmonary arterial hypertension (PAH) has led Raymond James to downgrade the rival PAH drug developer Gossamer Bio ( NASDAQ: GOSS ) to Market Perform from Outperform on T...